Saracatinib (AZD0530)

目录号：S1006

Molecular Weight(MW): 542.03

Saracatinib (AZD0530)是一种有效的Src抑制剂，无细胞试验中IC50为2.7 nM，对c-Yes， Fyn， Lyn， Blk， Fgr和Lck也具有活性；但对Abl和EGFR (L858R和L861Q)活性较低。Phase 2/3。

规格

价格

库存

购买数量

10mM/1mL In DMSO	RMB 746.35	现货
10mg	RMB 569.55	现货
25mg	RMB 1395.95	现货
200mg	RMB 5472.84	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献183篇：

Science, 2019, 365(6454)

PubMed: 31320558 ( click the link to review the publication )

Science, 2019, 365(6454)

PubMed: 31320558 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(1):35-49

PubMed: 29249464 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):807-822

PubMed: 30423298 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):296

PubMed: 30655532 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4349

PubMed: 31554791 ( click the link to review the publication )

J Exp Med, 2019, 216(4):807-830

PubMed: 30819724 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(5):1639-1649

PubMed: 30504425 ( click the link to review the publication )

J Cell Biol, 2019, 218(9):3060-3076

PubMed: 31308216 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Cancer Res, 2019, 79(19):5074-5087

PubMed: 31416844 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):132

PubMed: 31805962 ( click the link to review the publication )

Mol Metab, 2019, 28:36-47

PubMed: 31327757 ( click the link to review the publication )

Br J Cancer, 2019, 10.1038/s41416-019-0608-1

PubMed: 31649319 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2135-2145

PubMed: 31484705 ( click the link to review the publication )

J Immunol, 2019, 203(11):2990-2999

PubMed: 31619538 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2019, 316(3):C377-C392

PubMed: 30566391 ( click the link to review the publication )
BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Dev Comp Immunol, 2019, 96:1-8

PubMed: 30822451 ( click the link to review the publication )

Oncol Rep, 2019, 41(3):1911-1917

PubMed: 30628679 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3625-3632

PubMed: 31485668 ( click the link to review the publication )

Commun Biol, 2019, 2:156

PubMed: 31098401 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2068

PubMed: 29802342 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4259

PubMed: 30323235 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cancer Res, 2018, 78(4):985-1002.

PubMed: 29279356 ( click the link to review the publication )

Cancer Res, 2018, 78(22):6497-6508

PubMed: 30262461 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(21):2817-2836

PubMed: 29511352 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )

Oncogene, 2018, 37(23):3166-3182

PubMed: 29545604 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):887

PubMed: 30166523 ( click the link to review the publication )

FASEB J, 2018, 32(6):3033-3046

PubMed: 29401603 ( click the link to review the publication )

Neurobiol Dis, 2018, 110:102-121

PubMed: 29197620 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Metallomics, 2018, 10(8):1141-1159

PubMed: 30066004 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )
Exp Cell Res, 2018, 364(2):208-216

PubMed: 29427623 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )

Cancer Med, 2018, 7(2):408-419

PubMed: 29318780 ( click the link to review the publication )

Cancer Med, 2018, 7(3):820-830

PubMed: 29383859 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 502(1):110-115

PubMed: 29787755 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):447-454

PubMed: 29749519 ( click the link to review the publication )

Viruses, 2018, 10(6)

PubMed: 29795047 ( click the link to review the publication )

Tumour Biol, 2018, 40(8):1010428318794217

PubMed: 30124118 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10723-10733

PubMed: 29535838 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(2):106-119

PubMed: 28114269 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(2):106-119

PubMed: 28114269 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

J Clin Invest, 2017, 127(4):1338-1352

PubMed: 28240606 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

J Exp Med, 2017, 214(9):2715-2732

PubMed: 28838952 ( click the link to review the publication )

J Exp Med, 2017, 214(9):2715-2732

PubMed: 28838952 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):1643-1648

PubMed: 28130546 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )
J Cell Biol, 2017, 216(11):3571-3590

PubMed: 28972102 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2990-3000

PubMed: 28416483 ( click the link to review the publication )

Cell Rep, 2017, 20(12):2775-2783

PubMed: 28930674 ( click the link to review the publication )

Cell Rep, 2017, 20(4):999-1015

PubMed: 28746882 ( click the link to review the publication )

Cell Rep, 2017, 21(2):533-545

PubMed: 29020637 ( click the link to review the publication )

Cell Rep, 2017, 18(3):804-815

PubMed: 28099856 ( click the link to review the publication )

Cell Rep, 2017, 21(2):533-545

PubMed: 29020637 ( click the link to review the publication )

Sci Signal, 2017, 10(460)

PubMed: 28049762 ( click the link to review the publication )

J Med Chem, 2017, 60(18):7863-7875

PubMed: 28792760 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2572-2585

PubMed: 28830985 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

J Virol, 2017, 91(21)

PubMed: 28814523 ( click the link to review the publication )

PLoS Comput Biol, 2017, 13(3):e1005432

PubMed: 28306714 ( click the link to review the publication )

J Cancer, 2017, 8(11):1943-1951

PubMed: 28819393 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Leuk Res, 2017, 61:44-52

PubMed: 28888102 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):494-506

PubMed: 28346091 ( click the link to review the publication )

Cancer Genet, 2017, 216-217:128-141

PubMed: 29025587 ( click the link to review the publication )

Biotechnol J, 2017, 12(10)

PubMed: 28786556 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103014-103031

PubMed: 29262541 ( click the link to review the publication )

Oncotarget, 2017, 8(48):83872-83889

PubMed: 29137389 ( click the link to review the publication )
Oncotarget, 2017, 9(5):5545-5561

PubMed: 29464017 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Oncotarget, 2017, 8(61-:103014-103031

PubMed: 29262541 ( click the link to review the publication )

Sci Transl Med, 2016, 8(354):354ra114

PubMed: 27582059 ( click the link to review the publication )

Theranostics, 2016, 6(4):594-609

PubMed: 26941850 ( click the link to review the publication )

Sci Signal, 2016, 9(448):ra97

PubMed: 27703030 ( click the link to review the publication )

Brain Behav Immun, 2016, 55:236-248

PubMed: 26721416 ( click the link to review the publication )

Cell Death Dis, 2016, 7(12):e2572

PubMed: 28032865 ( click the link to review the publication )

PLoS Genet, 2016, 12(3):e1005931

PubMed: 26978032 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(9):2198-208

PubMed: 27256378 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(2):266-74

PubMed: 26604135 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(2):509-21

PubMed: 27186420 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(10):1555-68

PubMed: 26976639 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

Toxicology, 2016, 370:94-105

PubMed: 27693619 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 479(3):563-570

PubMed: 27666484 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45687-45701

PubMed: 27285768 ( click the link to review the publication )

Sci Signal, 2015, 8(400):ra106

PubMed: 26508788 ( click the link to review the publication )

Stem Cells, 2015, 10.1002/stem.1990

PubMed: 25788415 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2238-48

PubMed: 26208525 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10-:2238-48

PubMed: 26208525 ( click the link to review the publication )
Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):377-88

PubMed: 25306394 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(12):2687-96

PubMed: 26390252 ( click the link to review the publication )

FEBS J, 2015, 10.1111/febs.13314

PubMed: 25940608 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Pancreas, 2015, 44(1):152-7

PubMed: 25222135 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0142219

PubMed: 26556238 ( click the link to review the publication )

Mol Cell Biochem, 2015, 407(1-2):197-207

PubMed: 26045172 ( click the link to review the publication )

J Biomol Screen, 2015, 20(10):1286-93

PubMed: 26384394 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22098-113

PubMed: 26061747 ( click the link to review the publication )

Nature, 2015, 519(7541):57-62

PubMed: 25731159 ( click the link to review the publication )

Oncotarget, 2015, 6(28):26090-103

PubMed: 26325669 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22098-113

PubMed: 26061747 ( click the link to review the publication )

Oncotarget, 2015, 6(30):29991-30005

PubMed: 26358373 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9476-87

PubMed: 25823815 ( click the link to review the publication )

Neurotherapeutics, 2015, 12(1):132-42

PubMed: 25549849 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25897-916

PubMed: 26317790 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(5):401-14

PubMed: 24705551 ( click the link to review the publication )

J Clin Invest, 2014, 124(12):5490-502

PubMed: 25401474 ( click the link to review the publication )

J Clin Invest, 2014, 124(7):3003-15

PubMed: 24911146 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4762-71

PubMed: 25023728 ( click the link to review the publication )
Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(3):R45

PubMed: 24887236 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-38

PubMed: 24482380 ( click the link to review the publication )

Cancer Sci, 2014, 105(5):528-36

PubMed: 24612061 ( click the link to review the publication )

J Chem Inf Model, 2014, 54(3):881-93

PubMed: 24490903 ( click the link to review the publication )

Ultrasound Med Biol, 2014, 40(6):1177-86

PubMed: 24612644 ( click the link to review the publication )

Placenta, 2014, 35(10):824-30

PubMed: 25108485 ( click the link to review the publication )

Oncotarget, 2014, 6(3)

PubMed: 25596741 ( click the link to review the publication )

University of Manche, 2014, aus Landshut

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(19):8853-68

PubMed: 25326682 ( click the link to review the publication )

J Neurooncol, 2014, 120(1):33-41

PubMed: 25048528 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Pac Symp Biocomput, 2014, 2014:125-35

PubMed: 24297540 ( click the link to review the publication )

Dissertation zur Erlangung des Doktorgrades, 2014,

PubMed: ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Cell Biol, 2013, 15(4):395-405

PubMed: 23455479 ( click the link to review the publication )

Blood, 2013, 122(7):1203-13

PubMed: 23836556 ( click the link to review the publication )

J Clin Invest, 2013, 123(5):2037-48

PubMed: 23543053 ( click the link to review the publication )

J Clin Invest, 2013, 123(5):2037-48

PubMed: 23543053 ( click the link to review the publication )

Int J Cancer, 2013, 132(1):224-35

PubMed: 22623106 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(5):R85

PubMed: 24044505 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e915

PubMed: 24201814 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )
J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

Biochimica et Biophysica Acta, 2013, 1829(10):1147-59

PubMed: 23948603 ( click the link to review the publication )

Mol Carcinog, 2013, 10.1002/mc.22092

PubMed: 24127286 ( click the link to review the publication )

PLoS One, 2013, 8(4):e60889

PubMed: 23593342 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(6):379-88

PubMed: 22313687 ( click the link to review the publication )

Cancer Res, 2011, 71(24):7547-57

PubMed: 21994334 ( click the link to review the publication )

Mol Cancer Res, 2011, 9(3):249-58

PubMed: 21296861 ( click the link to review the publication )

Mol Endocrinol, 2011, 25(12):2041-53

PubMed: 22053001 ( click the link to review the publication )

Cancer Biol Ther, 2011, 12(3):215-28

PubMed: 21642769 ( click the link to review the publication )

Transl Oncol, 2011, 4(2):92-100

PubMed: 21461172 ( click the link to review the publication )

Methods Mol Biol, 2011, 685:91-109

PubMed: 20981520 ( click the link to review the publication )

Mol Endocrinol, 2010, 24(6):1151-64

PubMed: 20371703 ( click the link to review the publication )

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述

特性

Saracatinib是第一个作用于人类肿瘤组织Src通路的抑制剂。

靶点

c-Src ^[2] (Cell-free assay)	LCK ^[2] (Cell-free assay)	c-YES ^[2] (Cell-free assay)	EGFR (L861Q) ^[2] (Cell-free assay)	Lyn ^[2] (Cell-free assay)	点击更多
2.7 nM	<4 nM	4 nM	4 nM	5 nM	点击更多

体外研究

Saracatinib也有效抑制其他Src酪氨酸激酶家族成员，包括c-Yes, Fyn, Lyn, Blk, Fgr, 和Lck，IC50为4到10 nM。Saracatinib有效抑制SrcY530F突变的NIH 3T3细胞，IC50为80 nM。在NBT-II膀胱癌细胞中，Saracatinib显著阻断HT1080细胞通过立体骨胶原基质的入侵，且完全抑制EGF诱导的细胞分散。^[1]Saracatinib作用于DU145和PC3细胞，通过抑制Y419磷酸化而有效抑制Src激活。Saracatinib抑制前列腺癌包括PC3, DU145, CWR22Rv1和 LNCaP的生长，而Saracatinib作用于 LAPC-4, PZ-HPV7和RWPE-1细胞时却显示低活性。Saracatinib使细胞周期停止在G1/S期，但是不使caspase 3断裂。Saracatinib 也明显抑制Boyden 小室的DU145和PC3 移动。^[2]Saracatinib有效且持久抑制Akt，且增强A549和Calu-6细胞对放射处理的敏感性。^[3]Saracatinib在活性，再吸收，及组成上抑制蚀骨细胞。Saracatinib也可逆阻断蚀骨细胞前体的移动。^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
CTV-1	Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwME[xOFMh\|ryP	M2S4SnNCVkeHUh?=
LAMA-84	NFrvSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[wPGh7UUN3ME2wMlE2QTlizszN	M{LlUnNCVkeHUh?=
MEG-01	MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fMb2lEPTB;MD6yN\|Y5QCEQvF2=	MYrTRW5ITVJ?
EM-2	NGPaUIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwMk[1JO69VQ>?	NFS0eXZUSU6JRWK=
TE-15	M37J[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;seWlEPTB;MD6yO\|QyOiEQvF2=	M4e3R3NCVkeHUh?=
NCI-H1648	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwMkixNVYh\|ryP	NGC4WYJUSU6JRWK=
TE-12	NF7kN\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwM{K2PEDPxE1?	M1npVXNCVkeHUh?=
LB996-RCC	M3G5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF70R2dKSzVyPUCuOFQyQTZizszN	NIPZd5NUSU6JRWK=
K-562	NUPRTXFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV[4SWh3UUN3ME2wMlQ1QTZ5IN88US=>	Ml3BV2FPT0WU
D-336MG	M4PPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwNUCzNFQh\|ryP	M4i3ZXNCVkeHUh?=
NOS-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzaVVdKSzVyPUCuOlA2OjlizszN	MnSyV2FPT0WU
EW-24	Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlraTWM2OD1yLk[yOlk{KM7:TR?=	MnHnV2FPT0WU
BV-173	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHrXm5KSzVyPUCuOlUzPDlizszN	M3rrbXNCVkeHUh?=
NCCIT	MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwN{OyNVgh\|ryP	NV:zUJBkW0GQR1XS
NCI-H1436	NX7OO\|hLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwN{mwOFkh\|ryP	NEXiUYJUSU6JRWK=
BB30-HNC	NWnheJdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPKUXBKSzVyPUCuPFYzODNizszN	M1jzPHNCVkeHUh?=
TE-8	NV[wNZNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7YZ3dKSzVyPUCuPFczPzVizszN	MXLTRW5ITVJ?
A704	NHfxXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLNTWM2OD1yLki5NlEh\|ryP	MXvTRW5ITVJ?
TK10	M1TtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLuT2F6UUN3ME2wMlkxPjZ7IN88US=>	MWjTRW5ITVJ?
KS-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFv4TVlKSzVyPUGuNVk4PzlizszN	MnPmV2FPT0WU
C2BBe1	Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXRTWM2OD1zLkKwOVA4KM7:TR?=	NF\tVlZUSU6JRWK=
RXF393	NU[wNokxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEH4NWpKSzVyPUGuNlQ{PiEQvF2=	M3HrcHNCVkeHUh?=
KGN	M3fPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXLTWM2OD1zLkK3Olg4KM7:TR?=	MYjTRW5ITVJ?
NB69	NYrrNXdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTFwM{e0PVch\|ryP	MV;TRW5ITVJ?
TE-11	M4m4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTWTZRZUUN3ME2xMlQ{PDF6IN88US=>	Mlv5V2FPT0WU
TE-1	NGHnR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13WR2lEPTB;MT60OFExPSEQvF2=	M2q3TnNCVkeHUh?=
ST486	NH;GfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUKyXo9xUUN3ME2xMlQ2QDV{IN88US=>	MmLZV2FPT0WU
HOP-62	NFrRWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFwNUCyOFYh\|ryP	NWnwVYI{W0GQR1XS
EW-16	M{Lr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2D0TGlEPTB;MT61OVA5OyEQvF2=	NEfZfodUSU6JRWK=
LB1047-RCC	NGLCT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTFwNUW0OVMh\|ryP	M1fySXNCVkeHUh?=
TE-10	MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFywVoFKSzVyPUGuOlYzPTJizszN	MWnTRW5ITVJ?
RL95-2	M3vnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonHTWM2OD1zLk[2PVAzKM7:TR?=	MX7TRW5ITVJ?
DOHH-2	M3[y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHyTWM2OD1zLkexO\|gzKM7:TR?=	NHPNbodUSU6JRWK=
MFH-ino	NIL1NW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTFwN{e4O{DPxE1?	M1X6OHNCVkeHUh?=
GB-1	NH7Db5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkD5TWM2OD1zLke5PFM{KM7:TR?=	NITWdFZUSU6JRWK=
SK-N-DZ	MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojDTWM2OD1zLki0Olg5KM7:TR?=	NGjuUHVUSU6JRWK=
OS-RC-2	MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTFwOEi1O\|Qh\|ryP	MkW2V2FPT0WU
SW982	M2\heWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPTTWhKSzVyPUGuPVIxQTNizszN	MkXQV2FPT0WU
KALS-1	NX;KWmZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjETWM2OD1zLkm4O\|IzKM7:TR?=	NHG2dYdUSU6JRWK=
TGBC24TKB	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TseGlEPTB;Mj6wOVk2QCEQvF2=	NFy4[mhUSU6JRWK=
GI-1	M1Prbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGe5bWxKSzVyPUKuNVYxQDRizszN	MYfTRW5ITVJ?
SW962	MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUftS29nUUN3ME2yMlE4OTd6IN88US=>	MWPTRW5ITVJ?
SW872	Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjS[FRYUUN3ME2yMlE5PTB5IN88US=>	NVfldJp7W0GQR1XS
NCI-H747	M4Wxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUi4NXdIUUN3ME2yMlI2PzF2IN88US=>	MVLTRW5ITVJ?
MZ1-PC	NVv1TXdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDyeHlFUUN3ME2yMlI6OzV4IN88US=>	NGPyeo1USU6JRWK=
MSTO-211H	NUDhOnJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTJwM{W3NlMh\|ryP	MlfuV2FPT0WU
BL-70	MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTJwNEe0NlIh\|ryP	MVTTRW5ITVJ?
SW954	MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTJwNUe0NFgh\|ryP	MoLIV2FPT0WU
SNB75	Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTJwNki1PVQh\|ryP	MmHjV2FPT0WU
IST-SL2	NIPIelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjN[2lIUUN3ME2yMlczOzd7IN88US=>	MUPTRW5ITVJ?
GCIY	MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;R[5V3UUN3ME2yMlg4ODB3IN88US=>	MYjTRW5ITVJ?
KU812	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LrS2lEPTB;Mz6wOVI6QSEQvF2=	MV;TRW5ITVJ?
LXF-289	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2f4OWlEPTB;Mz6xNlExQSEQvF2=	MkjLV2FPT0WU
ETK-1	M1WxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXTUoY5UUN3ME2zMlIxPzZ5IN88US=>	NX3BRlB7W0GQR1XS
SF126	MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFSyc41KSzVyPUOuN\|EyPzRizszN	NGi3TmpUSU6JRWK=
LC-2-ad	NWrVe2NyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTNwNUW3JO69VQ>?	NH7GSVdUSU6JRWK=
KNS-42	NYrqOo5TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmf3TWM2OD1\|Lk[1JO69VQ>?	Mn7hV2FPT0WU
OVCAR-4	Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTNwN{O0N\|Mh\|ryP	NF:1eWpUSU6JRWK=
PF-382	NGrpdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rCZWlEPTB;Mz64N\|Y6QCEQvF2=	NGX2dXBUSU6JRWK=
SH-4	MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33qU2lEPTB;ND6yOVI2QSEQvF2=	MXnTRW5ITVJ?
KM12	NXrBfWlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:zd29KSzVyPUSuN\|I1OTZizszN	MmnzV2FPT0WU
NB5	MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXFTWM2OD12LkSxPFY1KM7:TR?=	NGfJVnFUSU6JRWK=
KURAMOCHI	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTRwNkWyOVYh\|ryP	MVXTRW5ITVJ?
Becker	M{XvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlW1TWM2OD12Lk[2OFE3KM7:TR?=	NIrEdHBUSU6JRWK=
MV-4-11	MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzVfY9KSzVyPUSuPFE{PDRizszN	NHHPZmhUSU6JRWK=
KINGS-1	NHv3SnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHQdlBKSzVyPUSuPFI{PzNizszN	MoXvV2FPT0WU
LS-123	NYPmXok6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLuTWM2OD13LkS5Olg1KM7:TR?=	NELnN\|ZUSU6JRWK=
SF268	NVXVUnRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHG0SmdKSzVyPUWuOlEzPjJizszN	M2jJbnNCVkeHUh?=
A388	NH7EV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2S2SGlEPTB;NT62N\|Y3PyEQvF2=	MnTxV2FPT0WU
NMC-G1	NYLxOHcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XuVmlEPTB;Nj6wNVgyOSEQvF2=	NH;SZmpUSU6JRWK=
CGTH-W-1	NUTKVmNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjaTWM2OD14LkCyNFc2KM7:TR?=	NHXtWYVUSU6JRWK=
ES4	MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTZwNUOwO\|Qh\|ryP	M{W5O3NCVkeHUh?=
SR	MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PROmlEPTB;Nj61PFgxPyEQvF2=	MlzwV2FPT0WU
BB49-HNC	NXnXVIY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWD1cJEzUUN3ME22Mlc{OjB4IN88US=>	NEm1OFhUSU6JRWK=
KLE	M3rXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIT3WFVKSzVyPU[uO\|g{PzdizszN	Ml;GV2FPT0WU
HUTU-80	NYmzeGtqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTZwOUi0OlYh\|ryP	MVvTRW5ITVJ?
SNU-C2B	NFfRUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;GN2tKSzVyPUeuPFI4OzdizszN	MVPTRW5ITVJ?
BB65-RCC	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnjTWM2OD15Lkm0PVA1KM7:TR?=	MVXTRW5ITVJ?
QIMR-WIL	NFLye25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTWNGRKSzVyPUiuOFI5ODhizszN	NWDjOnFiW0GQR1XS
GDM-1	NGPO[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\q[mlEPTB;OD65O\|I6OiEQvF2=	MV\TRW5ITVJ?
LC4-1	NIjKWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHNTIVCUUN3ME25MlAxQTFzIN88US=>	NXm0Toh6W0GQR1XS
MLMA	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;jZ2lEPTB;OT6xOVAxPiEQvF2=	NV;OXHFUW0GQR1XS
EoL-1-cell	NFTxSoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvPXYJKSzVyPUmuN\|AyQTJizszN	MXrTRW5ITVJ?
BOKU	MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrSTWM2OD17Lkm2OFY3KM7:TR?=	NUWzWZFHW0GQR1XS
EVSA-T	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTFyLk[1Olgh\|ryP	MWTTRW5ITVJ?
D-283MED	NEPh[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPOTWM2OD1zMD65NVc3KM7:TR?=	NGLWSoxUSU6JRWK=
NB1	M2e5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjvTWM2OD1zMT6wNlQzKM7:TR?=	MUTTRW5ITVJ?
RPMI-8402	M2frRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nHN2lEPTB;MUGuNVc5KM7:TR?=	NXu2bJdZW0GQR1XS
NCI-H1355	NF6zRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXyfmJ7UUN3ME2xNU4yQDB4IN88US=>	M3TSSnNCVkeHUh?=
NB7	NUnJRppUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\mcpVKSzVyPUGxMlMzQTdizszN	NFHGcXFUSU6JRWK=
RPMI-6666	M13CWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTF{Lkm1Olch\|ryP	NFS3WXhUSU6JRWK=
697	NG\uU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{Tyb2lEPTB;MUOuNlcxOSEQvF2=	MmDTV2FPT0WU
CTB-1	NW\ZOGU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvIfZlnUUN3ME2xN{42QTR6IN88US=>	Moi1V2FPT0WU
VA-ES-BJ	Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37RT2lEPTB;MUOuPVI{PCEQvF2=	NInT[2RUSU6JRWK=
BE-13	M{nlSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\VUmlEPTB;MUSuN\|kyPSEQvF2=	MYrTRW5ITVJ?
SKM-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTF2LkS0PVkh\|ryP	NU\BcoF7W0GQR1XS
TE-6	Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nCZWlEPTB;MUSuO\|U6OSEQvF2=	NGracYVUSU6JRWK=
LB771-HNC	NF3oN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTF2Lke4PVgh\|ryP	NGDBbXpUSU6JRWK=
ECC4	M4LlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEn5XnRKSzVyPUG3MlAzPzdizszN	NFvCSFBUSU6JRWK=
ES3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnLPIFlUUN3ME2xO{41PjV3IN88US=>	M1L2SHNCVkeHUh?=
LB647-SCLC	NWPweopHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmH4TWM2OD1zNz60PVQ6KM7:TR?=	NHrMZpVUSU6JRWK=
NB10	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{P6fmlEPTB;MUiuOVI2PiEQvF2=	M{HwNHNCVkeHUh?=
L-540	NGr3OldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fqWGlEPTB;MUiuPFExQSEQvF2=	M{jJN3NCVkeHUh?=
NCI-H2126	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fCSWlEPTB;MUmuOVEh\|ryP	NHn3TopUSU6JRWK=
HH	MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIP2R5hKSzVyPUKwMlAxQTlizszN	MWnTRW5ITVJ?
MPP-89	M{DNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXpTWM2OD1{Mz6yNlg6KM7:TR?=	M4PmTHNCVkeHUh?=
IST-MEL1	M1Xzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;zZlZKSzVyPUKzMlg3PThizszN	M4TzfXNCVkeHUh?=
KP-N-YS	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnSTZAxUUN3ME2yN{46OjV3IN88US=>	NVS0Z25PW0GQR1XS
EC-GI-10	NXiweG9GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LXW2lEPTB;MkSuOVk5QSEQvF2=	NEWzdnNUSU6JRWK=
EKVX	NHyyOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYr3VHBOUUN3ME2yOk4xOjB\|IN88US=>	M1Lh[3NCVkeHUh?=
TGBC1TKB	NEXie5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LDXmlEPTB;Mk[uOFM1KM7:TR?=	M1O4VXNCVkeHUh?=
Daudi	MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXlTWM2OD1{Nz6wO\|c{KM7:TR?=	MX\TRW5ITVJ?
ALL-PO	NW\DTmFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzBNnV6UUN3ME2yO{4xQDFizszN	NF7ufVNUSU6JRWK=
NB6	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jifGlEPTB;MkeuOFg5KM7:TR?=	MUPTRW5ITVJ?
ES6	MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTjTWM2OD1{Nz65NVI{KM7:TR?=	MlXOV2FPT0WU
COLO-320-HSR	MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTJ6LkCzO\|Mh\|ryP	MXrTRW5ITVJ?
K5	MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX32[XZJUUN3ME2yPE4yOjh5IN88US=>	Mkm5V2FPT0WU
ES1	M17icWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rqR2lEPTB;MkiuO\|c4OyEQvF2=	MkHkV2FPT0WU
LC-1F	MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HqOWlEPTB;MkmuO\|M1PiEQvF2=	M3;WNXNCVkeHUh?=
SCLC-21H	MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfrTWM2OD1\|MD63N\|E4KM7:TR?=	NXHMZmJOW0GQR1XS
SK-PN-DW	MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTN{LkW1PVgh\|ryP	NUjSXoJlW0GQR1XS
D-247MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTN{Lkm3O\|Mh\|ryP	M2HrRnNCVkeHUh?=
TE-5	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHrTWM2OD1\|Mz6wN\|YzKM7:TR?=	MUXTRW5ITVJ?
MONO-MAC-6	M1[0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTzOXRKSzVyPUOzMlUxPDhizszN	MoHzV2FPT0WU
LB2518-MEL	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULze\|A2UUN3ME2zN{44PjZ4IN88US=>	M4ruPHNCVkeHUh?=
LOXIMVI	NHrJZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzlSXdYUUN3ME2zN{44QTJ6IN88US=>	NXOwVWVlW0GQR1XS
NCI-H209	MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvmTWM2OD1\|NT6xOFQh\|ryP	MVHTRW5ITVJ?
A253	NV\He4hqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\rS2VKUUN3ME2zOU44PDJ7IN88US=>	Mkj3V2FPT0WU
HCC1599	NYq0dIdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTN4LkewOVMh\|ryP	NGruVnlUSU6JRWK=
EB-3	M4Dx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkP2TWM2OD1\|Nj65OVE5KM7:TR?=	NYLTd\|h2W0GQR1XS
GOTO	MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTN5LkOyNlQh\|ryP	NUnGSXJWW0GQR1XS
SW684	MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfwTWM2OD12MT64OFk2KM7:TR?=	MlLOV2FPT0WU
DEL	NUfzN\|ZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TiZ2lEPTB;NEKuNFUzOiEQvF2=	NVfDZmY1W0GQR1XS
HT-144	M2\GSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrPV3d7UUN3ME20Nk4yPjd4IN88US=>	M2C0WXNCVkeHUh?=
TE-9	Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmX2TWM2OD12Mz60OVk3KM7:TR?=	NFPZZYxUSU6JRWK=
KARPAS-45	M1LwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nvd2lEPTB;NESuN\|kzPSEQvF2=	M{TwV3NCVkeHUh?=
HAL-01	M{HjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2faeWlEPTB;NESuOVA{PCEQvF2=	NVmwXFl{W0GQR1XS
RCC10RGB	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTR2LkezPVIh\|ryP	NV7tdFFXW0GQR1XS
CP67-MEL	MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fYUGlEPTB;NEWuOlI1OSEQvF2=	MmnKV2FPT0WU
NB17	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTR3Lk[2OFMh\|ryP	NIfrbVVUSU6JRWK=
SK-UT-1	NVm2T29yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\sc\|VKSzVyPUS1Mlk1PjRizszN	M{DUSnNCVkeHUh?=
JiyoyeP-2003	NYT6e4EzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3JUFZLUUN3ME20Ok4xOTF7IN88US=>	Ml;UV2FPT0WU
HCE-4	MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2P6WWlEPTB;NE[uOVk3QCEQvF2=	MUPTRW5ITVJ?
NCI-H720	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTR4Lke2PFIh\|ryP	M37ES3NCVkeHUh?=
KARPAS-422	NU\x[I43T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTR5LkC4PVUh\|ryP	MUTTRW5ITVJ?
Ramos-2G6-4C10	NWO1b4d7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTR5LkG2NlIh\|ryP	M17MTnNCVkeHUh?=
HCE-T	NWO3UWF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHztNnZKSzVyPUS3MlY5OjhizszN	M3vUXnNCVkeHUh?=
PSN1	NXLudYRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3S5N2lEPTB;NEeuO\|gyOyEQvF2=	Ml\nV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pY576-FAK / pY861-FAK / FAK; PubMed: 20551056 Cancer Res (A) HCT116 (left) and WiDr (right) cells were exposed to the indicated concentrations of saracatinib for 24 hours and the effect on total FAK or FAK phosphorylation on tyrosine 576 or 861 was assessed by western blotting. Result is representative of three independent experiments. pY418 Src / Src / pY410 CAS / CAS / Py421 Cortactin / Cortactin; PubMed: 20505783 J Cancer Sci Ther Saracatinib inhibits Src activity and downstream Src substrate phosphorylation in HNSCC cell lines. HN31, UMSCC1 and 1483 cells were treated with DMSO vehicle or saracatinib (0.01–1 μM) for 24 h. Cells were lysed and total protein amounts were analyzed by Western blotting with total or phosphorylation site-specific antibodies for Src and the indicated substrates. Blots shown are representative of at least four independent experiments, with band intensities for each substrate quantified relative to the untreated (0 μM) condition for each cell line. p-Akt / p-mTOR / Akt / mTOR / p-S6 / S6 / p-AMPKα / AMPKα; PubMed: 20811583 Genes Cancer PC3 cells were treated with 10 μM PP2 (left panel)/1 μM saracatinib (right panel) for 0.5, 1, 2, 4, 8, and 24 h. Cell lysates were analyzed by immunoblotting with antibodies as indicated. Controls were treated with vehicle alone. β-actin was detected as loading control.	20551056 20505783 20811583
Growth inhibition assay	Cell number; PubMed: 24349321 PLoS One LNCaP 104-S, 104-R1, 104-R2, PC-3, and DU-145 cells were treated with increasing concentrations of Saracatinib for 72 hrs. Relative cell number of LNCaP cells was determined by Hoechst dye 33258-based 96-well proliferation assay. Cell numbers were normalized to control (dimethylsulfoxide) of each cell line. Triple asterisks (***) represent statistically significant difference p <0.001 between the treated group and the control group.	24349321

体内研究

Saracatinib作用于Src3T3异体移植物显示出强的肿瘤生长抑制率，且Saracatinib造成Calu-6, MDA-MB-231, AsPc-1和BT474C移植瘤生长适当延迟。^[1]Saracatinib处理常位DU145鼠，按鼠体重，每千克每天口服处理25mg Saracatinib，结果显示出强的抗癌活性。^[2]

激酶实验： ^[1]	- 合并激酶实验: 使用受体和非受体酪氨酸激酶的重组催化区，通过酶联免疫吸附法测定酪氨酸激酶活性的IC50值。加入的Saracatinib剂量从0.001到10 mM不等。针对丝氨酸/苏氨酸激酶的特定实验是加³²P 的渗透捕捉实验。在加入10 μL 20mM Mg.ATP开始反应前，包含0.5 μL Saracatinib或DMSO（作对照) 或pH 3.0 buffer（作对照）的多支路384孔板加入15 μL酶和肽/蛋白底物温育5分钟。所有酶的最终浓度都接近米氏常数（K_m）。实验在室温下进行30分钟，然后加入5 μL正磷酸终止反应。混合后，孔中的内含物加到P81联合板上，使用正磷酸作为洗涤缓冲液，然后计算IC50值。
细胞实验： ^[2]	- 合并 Cell lines: PC3, DU145, CWR22Rv1, LNCaP, LAPC-4, PZ-HPV7，和RWPE-1细胞 Concentrations: 62.5 nM-16 mM Incubation Time: 1, 3，和5天 Method: PC3, DU145, CWR22Rv1, LNCaP, LAPC-4, PZ-HPV7 及RWPE-1细胞按2×10³密度接种在96孔板上，温育过夜。加入浓度不等（62.5 nM-16 mM）的Saracatinib。1,3,5天后分离培养基，每孔加入0.2 mL DMSO，按每分钟200轮持续震荡96孔板15分钟。MTT实验测IC50值。 (Only for Reference)
动物实验： ^[2]	- 合并 Animal Models: 移植DU145细胞的CB17鼠 Formulation: 溶于0.5% 羟丙基甲基纤维素和0.1% Tween-80中 Dosages: 25 mg/kg Administration: 每天口服处理 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	35 mg/mL warmed (64.57 mM)
	Ethanol	31 mg/mL (57.19 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+30% PEG 300+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Saracatinib (AZD0530) SDF

分子量	542.03
化学式	C₂₇H₃₂ClN₅O₅
CAS号	379231-04-6
储存条件	3年 -20°C粉状
储存条件	2年 -80°C 溶于溶剂
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02085603	Completed	Drug: Saracatinib\|Drug: Placebo	Cancer	Sheffield Teaching Hospitals NHS Foundation Trust\|AstraZeneca	March 2014	Phase 2
NCT01864655	Completed	Drug: saracatinib\|Drug: Placebo	Alzheimer''s Disease	Stephen M. Strittmatter\|Yale University	July 2013	Phase 1
NCT01000896	Withdrawn	Drug: AZD0530\|Drug: Carboplatin\|Drug: paclitaxel	Cancer\|Non Small Cell Lung Cancer\|Epithelial Ovarian Cancer	AstraZeneca	January 2010	Phase 1
NCT00853983	Completed	Drug: [14C] AZD0530	Healthy	AstraZeneca	March 2009	Phase 1
NCT00752206	Completed	Drug: Saracatinib\|Drug: Placebo	Osteosarcoma	Sarcoma Alliance for Research through Collaboration\|AstraZeneca	March 2009	Phase 2
NCT00771979	Completed	Drug: AZD0530	Healthy	AstraZeneca	November 2008	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What is the half-life of Saracatinib?
回答：
Based on the following paper, the half-life of Saracatinib in vivo is around 40hours and it reaches its peak lever around 2-4 hours after dosing: http://clincancerres.aacrjournals.org/content/16/19/4876.long

Src Signaling Pathway Map

Src Inhibitors with Unique Features

活性最高的Src抑制剂

Dasatinib : Src, IC50=0.8 nM.
FDA批准的Src抑制剂

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
最新的Src抑制剂

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
经典的Src抑制剂

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

研究领域

产品类型

Saracatinib (AZD0530)

客户使用Selleck该产品发表文献183篇：

产品安全说明书

Src抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Saracatinib (AZD0530) SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技术支持

常见问题及建议解决方法

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品